FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN ISSUER
------------------------------------------
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2008
Commission File No. 000-30752
AETERNA ZENTARIS INC.
------------------------------------------
1405, boul. du Parc-Technologique
Quebec, Quebec
Canada, G1P 4P5
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F.
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
-------
DOCUMENTS INDEX
DOCUMENTS DESCRIPTION
1. Press Release dated June 27, 2008: AEterna Zentaris Sells Quebec City
Building for $7.1 million
[AETERNA ZENTARIS LOGO]
AETERNA ZENTARIS INC. 1405 du Parc-Technologique Blvd.
Quebec (Quebec) Canada G1P 4P5 T 418 652-8525 F 418 652-0881
www.aezsinc.com
PRESS RELEASE
For immediate release
AETERNA ZENTARIS SELLS QUEBEC CITY BUILDING FOR $7.1 MILLION
ALL AMOUNTS ARE IN U.S. DOLLARS
QUEBEC CITY, CANADA, JUNE 27, 2008 - Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX:
AEZ;), a global biopharmaceutical company focused on endocrine therapy and
oncology, today announced it has completed the sale of its Quebec City property
for a purchase price of $7.1 million, payable in cash. Aeterna Zentaris also
entered into a long-term lease agreement enabling the Company to continue
occupying its current space for its Quebec City operations.
Juergen Ernst, Chairman and Interim President and CEO of Aeterna Zentaris
stated, " We are very pleased to have completed the sale of our Quebec City
property. This is in line with our corporate strategy which includes divesting
non-core assets to provide additional non-dilutive financing. The funds will be
dedicated to our ongoing Phase 3 program with cetrorelix in benign prostatic
hyperplasia."
ABOUT AETERNA ZENTARIS INC.
Aeterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine
therapy and oncology, with proven expertise in drug discovery, development and
commercialization.
News releases and additional information are available at www.aezsinc.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements made pursuant to the safe
harbor provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties,
which could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability of the Company
to take advantage of business opportunities in the pharmaceutical industry,
uncertainties related to the regulatory process and general changes in economic
conditions. Investors should consult the Company's quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on
risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does not
undertake to update these forward-looking statements. We disclaim any obligation
to update any such factors or to publicly announce the result of any revisions
to any of the forward-looking statements contained herein to reflect future
results, events or developments except if we are requested by a governmental
authority or applicable law.
CONTACTS
Dennis Turpin, CA
Senior Vice President and Chief Financial Officer
(908) 626-5503
dturpin@aezsinc.com
MEDIA RELATIONS
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
pburroughs@aezsinc.com
-30-
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
AETERNA ZENTARIS INC.
Date: June 30, 2008 By: /s/ Dennis Turpin
-------------------- ----------------------------------------------
Dennis Turpin
Senior Vice President, Chief Financial Officer